Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CF PharmTech Raises $90M Investment | Contract Pharma
Breaking News

CF PharmTech Raises $90M Investment

Aims to advance respiratory drug products in its pipeline to market

CF PharmTech, Inc., a pharmaceutical company focused on respiratory drug products, has raised a $90 million Series E investment led by New Alliance Capital. The investment will allow CF PharmTech to advance products in its pipeline to market. 
 
New Alliance Capital Executive Director Lei Cai said, “New Alliance Capital prioritizes investment opportunities in the healthcare industries. Respiratory treatments and inhaled medications, in particular, are promising because of the high technological barriers to entry and immense potential for growth. CF PharmTech has worked meticulously to build strong technological platforms that support the development of a comprehensive range of products. The integrity and professionalism of the core team at CF PharmTech impressed us deeply.”

CR-CP Life Science Fund Managing Director Da Liu said, “CF PharmTech is one of China’s most innovative and pioneering pharmaceutical companies to focus on respiratory disease treatments. As a pharma company, CF PharmTech fully embodies a commitment to quality and global standards. As one of the few leading private pharmaceutical companies of respiratory drug delivery, CF PharmTech has immense potential for growth.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters